Romifidine

Romifidine

SCHEMBL29761110

Fc1cccc(Br)c1NC1=NCCN1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2C P18825 13/20 0.56
ADRA2A P08913 12/20 0.56
ADRA2B P18089 12/20 0.56
ADRA1A P35348 5/20 0.56
ADRA1D P25100 4/20 0.56
ADRA1B P35368 4/20 0.56
HTR1D P28221 3/20 0.56
LMNA P02545 2/20 0.56
CYP2D6 P10635 2/20 0.56
NISCH Q9Y2I1 2/20 0.56
MEN1 O00255 1/20 0.56
SLC22A1 O15245 1/20 0.56
SLC22A3 O75751 1/20 0.56
HTR1A P08908 1/20 0.56
CYP2C9 P11712 1/20 0.56
HRH2 P25021 1/20 0.56
CYP2C19 P33261 1/20 0.56
OPRK1 P41145 1/20 0.56
KMT2A Q03164 1/20 0.56
HIF1A Q16665 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Romifidine SCHEMBL246009 1.00 ADRA2C (0.56) ADRA2CADRA2AADRA2BADRA1AADRA1D
Romifidine SCHEMBL1970327 0.98 ADRA2C (0.57) ADRA2CADRA2AADRA2BADRA1AADRA1D
Romifidine SCHEMBL22616284 0.98 ADRA2C (0.55) ADRA2CADRA2AADRA2BADRA1AADRA1D
Romifidine SCHEMBL22616255 0.92 ADRA2C (0.49) ADRA2CADRA2AADRA2BADRA1AADRA1D
Romifidine SCHEMBL22616210 0.92 ADRA2C (0.49) ADRA2CADRA2AADRA2BADRA1AADRA1D
Romifidine SCHEMBL22616229 0.91 ADRA2C (0.48) ADRA2CADRA2AADRA2BADRA1AADRA1D
Romifidine SCHEMBL22616310 0.90 HTR1D (0.50) ADRA2CADRA2AADRA2BADRA1AADRA1D
SCHEMBL11182818 0.89 ADRA2C (0.65) ADRA2CADRA2AADRA2BADRA1AADRA1D
SCHEMBL9920134 0.89 ADRA2C (0.65) ADRA2CADRA2AADRA2BADRA1AADRA1D
Romifidine SCHEMBL22616282 0.89 ADRA2A (0.46) ADRA2CADRA2AADRA2BADRA1AADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213647-A1 CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE UNIVERSITY OF SOUTH FLORIDA 2025-07-03 US claimed
WO-2023192319-A1 CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE UNIVERSITY OF SOUTH FLORIDA (US) 2023-10-05 WO claimed
US-20250367232-A1 HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY HUTCHINSON FRED CANCER RES (US) 2025-12-04 US disclosed
US-20250213647-A1 CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE UNIVERSITY OF SOUTH FLORIDA 2025-07-03 US disclosed
US-12016880-B2 Halogen treatment of heart attack and ischemic injury FRED HUTCHINSON CANCER CENTER (US) 2024-06-25 US disclosed
WO-2023192319-A1 CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE UNIVERSITY OF SOUTH FLORIDA (US) 2023-10-05 WO disclosed
US-20220313730-A1 HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY FRED HUTCHINSON CANCER CENTER 2022-10-06 US disclosed
US-20220211672-A1 METHODS OF TREATING PRURITUS CLEXIO BIOSCIENCES LTD. (IL) 2022-07-07 US disclosed